pSivida breaks BrachySil into Chinese market - correction:
This article was originally published in Clinica
In Clinica No 1180 (November 4 2005), we stated erroneously on page 14 that Perth, Western Australia-based pSivida was to pay Beijing Med-Pharm upfront and milestone payments totalling more than $2m for the distribution of pSivida's BrachySil in China. This should have read that pSivida will receive upfront and milestone payments from Beijing Med-Pharm for BrachySil. The modified silicon product that is just entering phase IIb trials as a potential new treatment for primary liver cancer.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.